TG Therapeutics
TGTX
183 hedge funds and large institutions have $595M invested in TG Therapeutics in 2022 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 63 increasing their positions, 56 reducing their positions, and 24 closing their positions.
235% more call options, than puts
Call options by funds: $42.6M | Put options by funds: $12.7M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
38% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 24
31% more capital invested
Capital invested by funds: $454M → $595M (+$140M)
13% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 56
5% more funds holding
Funds holding: 174 → 183 (+9)
4.7% less ownership
Funds ownership: 73.67% → 68.97% (-4.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.3M |
| 2 |
PL
Parkwood LLC
Cleveland,
Ohio
|
+$9.33M |
| 3 |
MC
Maverick Capital
Dallas,
Texas
|
+$6.26M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$6.13M |
| 5 |
Goldman Sachs
New York
|
+$3.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$16.3M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$10.8M |
| 3 |
Morgan Stanley
New York
|
-$9.98M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$8.88M |
| 5 |
Renaissance Technologies
New York
|
-$6.57M |
TGTX Hedge Fund Activity: Q3 2022 in Review
183 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q3 2022, worth a combined $595M — up 31% from $454M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new TGTX positions and 24 closed out — a net gain of 9 holders — while 63 added to existing stakes and 56 trimmed.
The largest buyer was Vanguard Group, adding an estimated $11.3M. The largest seller was State Street, cutting an estimated $16.3M.
- 183 institutional investors held TG Therapeutics (TGTX) as of Q3 2022, up from 174 in Q2 2022.
- Funds reported $595M of TG Therapeutics stock for Q3 2022, up 31% quarter-over-quarter.
- 33 funds opened new TG Therapeutics positions in Q3 2022 and 24 closed out, a net change of +9 holders.
- The largest TG Therapeutics buyer in Q3 2022 was Vanguard Group, an estimated $11.3M added.
- The largest TG Therapeutics seller in Q3 2022 was State Street, an estimated $16.3M sold.
Based on aggregated 13F filings for Q3 2022.